SQUAWK/NEWS
Account
Account
Menu
Live NewsCategoriesequity

Quest Diagnostics Incorporated (DGX) News

Track canonical SquawkNews coverage tagged to DGX, Quest Diagnostics Incorporated. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 22 indexed stories across 8 publication days and is ordered by the same first-publication timeline used by LiveCast.

Symbol DGX Asset equity Sector Markets 90 days 22 Last 237.78 Updated Aug 12, 2026, 08:15 PM UTC Open live news feed
L DGX Declares Quarterly Cash Dividend Quest Diagnostics declares quarterly cash dividend EQUITY | Aug 12, 2026, 08:15 PM UTC H DGXX DGX DGX - Digi Power X to Announce 2026 Q2 Financial Results and Provide Operations Update on August 14th DGXX DGX DGX - Digi Power X to Announce 2026 Q2 Financial Results and Provide Operations Update on August 14th EARNINGS | Aug 04, 2026, 11:30 AM UTC M Quest Diagnostics: BV linked to STI co-infection Quest Diagnostics study finds bacterial vaginosis link EQUITY | Jul 30, 2026, 11:32 AM UTC L Quest Diagnostics price target raised by $20 at BofA, here's why Quest Diagnostics price target raised by $20 at BofA, here's why EQUITY | Jul 24, 2026, 02:11 PM UTC L AMBP CVS DGX DOW UNP CYH MBLY NVR PKG ROL TMUS PT changes @ UBS AMBP CVS DGX DOW UNP CYH MBLY NVR PKG ROL TMUS PT changes @ UBS EQUITY | Jul 24, 2026, 12:34 PM UTC L DGX Big beat & raise on organic volume; Utilization healthy, despite debate; Reiterate Buy @ BAML DGX Big beat & raise on organic volume; Utilization healthy, despite debate; Reiterate Buy @ BAML EQUITY | Jul 24, 2026, 12:28 PM UTC H Americans Are Buying More Preventive Health Tests—and Quest Diagnostics Is Winning Quest Diagnostics Incorporated (NYSE: DGX ) stock surged Thursday after the diagnostic testing company reported second-quarter results that topped Wall Street expectations and raised its full-year 2026 guidance. Earnings EARNINGS | Jul 23, 2026, 05:47 PM UTC L Outperformers vs S&P sector ETFs (% chg vs ETF) Consumer Discretionary (XLY) - WYNN +7.20%, TSCO +6.63%, LVS +5.93%, YUM +4.79%, GRMN +4.78% Outperformers vs S&P sector ETFs (% chg vs ETF) Consumer Discretionary (XLY) - WYNN +7.20%, TSCO +6.63%, LVS +5.93%, YUM +4.79%, GRMN +4.78% Consumer Staples (XLP) - CASY +3.38%, MO +1.29%, ADM +1.01%, PEP +0.83%, BG +0. RATES | Jul 23, 2026, 04:00 PM UTC H Lockheed Martin, Quest Diagnostics, Thermo Fisher Scientific And Other Big Stocks Moving Higher On Thursday U.S. stocks were lower, with the Dow Jones index dipping around 450 points on Thursday. Shares of Lockheed Martin Corp (NYSE: LMT ) rose sharply after the company reported better-than-expected second-quarter financial re EARNINGS | Jul 23, 2026, 02:20 PM UTC L DGX +11% after Co forecasts annual revenue, profit above estimates DGX +11% after Co forecasts annual revenue, profit above estimates EARNINGS | Jul 23, 2026, 01:34 PM UTC H Transcript: Quest Diagnostics Q2 2026 Earnings Conference Call Quest Diagnostics (NYSE: DGX ) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered APIs. For comprehensiv EARNINGS | Jul 23, 2026, 01:33 PM UTC L DGX Quest Diagnostics exec notes expects Nova expenses in second half to account for about 70% of full-year total, vs prior expectation of 6 DGX Quest Diagnostics exec notes expects Nova expenses in second half to account for about 70% of full-year total, vs prior expectation of 60% - conf call RATES | Jul 23, 2026, 12:59 PM UTC H among early movers from the earnings calendar this morning gainers NVCR +15.6%, CLF +15.3%, AMBP +10.2%, COCO +9.9%, WST +9.6%, ALLE +8.4%, among early movers from the earnings calendar this morning gainers NVCR +15.6%, CLF +15.3%, AMBP +10.2%, COCO +9.9%, WST +9.6%, ALLE +8.4%, DGX +8.2%, ROP +6.2%, TMO +5.6%, IMAX +5.6%, IBCP +5.5%, RTX +5.3%, LMT +5.3%, H EARNINGS | Jul 23, 2026, 12:52 PM UTC L DGX +7% premarket after results DGX +7% premarket after results EQUITY | Jul 23, 2026, 12:14 PM UTC L Quest Diagnostics ups FY26 adjusted EPS view to $11.05-$11.25 from $10.63-$10.83 Consensus $10.77. Raises... EARNINGS | Jul 23, 2026, 10:51 AM UTC L Quest Diagnostics reports Q2 adjusted EPS $3.12, consensus $2.82 Reports Q2 revenue... EQUITY | Jul 23, 2026, 10:49 AM UTC H Quest Diagnostics Raises FY2026 GAAP EPS Guidance from $9.58-$9.78 to $9.97-$10.17 vs $9.60 Est Quest Diagnostics (NYSE: DGX ) raises FY2026 GAAP EPS guidance from $9.58-$9.78 to $9.97-$10.17 vs $9.60 analyst estimate.. EARNINGS | Jul 23, 2026, 10:46 AM UTC H DGX Quest Diagnostics RESULTS: Q2, Q2 REV $3.043B vs. EST $2.967B, Q2 EPS $2.84, Q2 Net Income $320M, Q2 ADJ EPS $3.12 vs. EST $2.83, Quest DGX Quest Diagnostics RESULTS: Q2, Q2 REV $3.043B vs. EST $2.967B, Q2 EPS $2.84, Q2 Net Income $320M, Q2 ADJ EPS $3.12 vs. EST $2.83, Quest Diagnostics Earnings Notes:, Outlook FY REV $11,950-12.050B vs. EST $11.851B, Ou RATES | Jul 23, 2026, 10:45 AM UTC L Implied EPS movers for tomorrow AM: TMO +/-5.2%, HON +/-4.6%, TMUS +/-4.8%, RTX +/-4.3%, INFY +/-16.4%, CMCSA +/-5.1%, UNP +/-3.7%, TECK +/ Implied EPS movers for tomorrow AM: TMO +/-5.2%, HON +/-4.6%, TMUS +/-4.8%, RTX +/-4.3%, INFY +/-16.4%, CMCSA +/-5.1%, UNP +/-3.7%, TECK +/-4.4%, FCX +/-5.1%, AAL +/-5.8%, LMT +/-4.6%, NDAQ +/-3.7%, BX +/-4.0%, ROP +/-8. EARNINGS | Jul 22, 2026, 06:29 PM UTC L BMY NVDA Bristol Myers buys Nvidia's latest AI Computing system for drug research New York, July 20 (Reuters) - Bristol Myers Squibb (BMY) s BMY NVDA Bristol Myers buys Nvidia's latest AI Computing system for drug research New York, July 20 (Reuters) - Bristol Myers Squibb (BMY) said on Monday it is buying the latest-generation Computing system from chip comp EQUITY | Jul 20, 2026, 11:00 AM UTC M DGX Gets NY Approval Quest Diagnostics receives New York's Department of Health's approval for its Haystack Minimal Residual Disease liquid biopsy test EQUITY | Jun 24, 2026, 12:57 PM UTC L DGX - Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Quest Diagnostics receives New York State approval for Haystack MRD, broadening patient access to ctDNA minimal residual disease testing EQUITY | Jun 24, 2026, 12:54 PM UTC